APLS · As filed with the SEC
Apellis Pharmaceuticals balance sheet, by quarter
The statement as Apellis Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Balance Sheets · USD
| USD | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 405,207,000 | 466,233,000 | 479,171,000 | 370,036,000 |
| Accounts receivable, net | 440,299,000 | 366,221,000 | 345,538,000 | 214,131,000 |
| Inventory | 131,408,000 | 142,556,000 | 122,819,000 | 121,000,000 |
| Prepaid assets | — | — | 31,560,000 | 29,171,000 |
| Prepaid and other current assets | 49,587,000 | 38,303,000 | — | — |
| Restricted cash | 1,520,000 | 1,527,000 | 1,430,000 | 1,430,000 |
| Other current assets | — | — | 10,158,000 | 19,842,000 |
| Total current assets | 1,028,021,000 | 1,014,840,000 | 990,676,000 | 755,610,000 |
| Non-current assets: | ||||
| Right-of-use assets | 18,945,000 | 18,195,000 | 19,720,000 | 14,637,000 |
| Property and equipment, net | 1,418,000 | 1,708,000 | 1,927,000 | 2,117,000 |
| Long-term inventory | 28,489,000 | 34,959,000 | 40,909,000 | 48,128,000 |
| Other assets | 5,659,000 | 5,555,000 | 5,491,000 | 898,000 |
| Total assets | 1,082,532,000 | 1,075,257,000 | 1,058,723,000 | 821,390,000 |
| Liabilities and Stockholders' Equity | ||||
| Current liabilities: | ||||
| Accounts payable | 49,049,000 | 56,798,000 | 38,602,000 | 54,241,000 |
| Accrued expenses | 133,693,000 | 166,049,000 | 140,322,000 | 138,999,000 |
| Convertible senior notes | 93,744,000 | 93,662,000 | 93,581,000 | — |
| Current portion of lease liabilities | 6,962,000 | 7,087,000 | 7,022,000 | 7,419,000 |
| Total current liabilities | 283,448,000 | 323,596,000 | 279,527,000 | 200,659,000 |
| Long-term liabilities: | ||||
| Long-term credit facility | 362,243,000 | 361,664,000 | 361,091,000 | 360,535,000 |
| Convertible senior notes | — | 0 | 0 | 93,500,000 |
| Lease liabilities | 12,807,000 | 11,947,000 | 13,680,000 | 8,313,000 |
| Other liabilities | 9,111,000 | 7,903,000 | 3,257,000 | 2,078,000 |
| Total liabilities | 667,609,000 | 705,110,000 | 657,555,000 | 665,085,000 |
| Stockholders' equity: | ||||
| Preferred stock, $0.0001 par value; 10,000 shares authorized, and no shares issued and outstanding at March 31, 2026 and December 31, 2025 | 0 | 0 | 0 | 0 |
| Common stock, $0.0001 par value; 200,000 shares authorized at March 31, 2026 and December 31, 2025; 127,923 shares issued and outstanding at March 31, 2026, and 126,621 shares issued and outstanding at December 31, 2025 | 13,000 | 12,000 | 12,000 | 12,000 |
| Additional paid-in capital | 3,411,643,000 | 3,385,216,000 | 3,357,583,000 | 3,328,604,000 |
| Accumulated other comprehensive loss | (2,411,000) | (2,103,000) | (2,400,000) | (2,569,000) |
| Accumulated deficit | (2,994,322,000) | (3,012,978,000) | (2,954,027,000) | (3,169,742,000) |
| Total stockholders' equity | 414,923,000 | 370,147,000 | 401,168,000 | 156,305,000 |
| Total liabilities and stockholders' equity | 1,082,532,000 | 1,075,257,000 | 1,058,723,000 | 821,390,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.